STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...

Please provide your email address to receive an email when new articles are posted on . Visual acuity increased by 3 letters on average at year 1. By year 6, annual decreases led to a net loss of 4.6 ...

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

Please provide your email address to receive an email when new articles are posted on . The average number of annual injections decreased from 8.7 in year 1 to 4.7 in year 7. The regimen could reduce ...

Sticking to the treatment schedule can be especially difficult. After you’re diagnosed, you usually need to have anti-VEGF injections about once a month, says Purnima Patel, MD, a clinical ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

Anti-VEGF drugs are associated with kidney injury for some patients, but no particular anti-VEGF has a stronger association than any others. The risk of kidney failure for people who receive ...